HOUSTON–Oncolin Therapeutics, Inc. is pleased to announce that Dr Randall K. Johnson has agreed to join the Scientific Advisory Board of the company joining a growing number of illustrious oncologists and cancer drug developers. Dr Johnson began his career as section Head of the Experimental Chemotherapy at the National Cancer Institute. Most of his accomplishments occurred over more than twenty years at Glaxo SmithKline where he held various senior positions in oncology culminating in Oncology Group Director. Among the many accomplishments during his tenure was the development of Topotecan which continues to be a major drug used in cancer therapy today. For the past five years Dr Johnson has consulted for numerous drug and biotech companies and is a member of many Scientific Advisory Boards and clinical advisory Boards for oncology based companies.
�We are very excited to have someone with Dr Johnson�s commercial oncology development experience as an advisor and consultant to our company. Once we complete our scientific advisory board we will have one of the top SABs in the nation and it will be staffed with some of the leading inventors and innovators in the cancer treatment space,� said Dr Donald Picker, President and COO.
Recent News
Oncolin announces its lead technology has shown to be effective in treating cancer in animal models.
Oncolin Therapeutics Obtains an Exclusive Worldwide Right to Option Patents Covering the Composition and Use of Genistein Analogs for Cancer Treatment
Oncolin has recently announced that is has obtained an exclusive option agreement with the Pharmaceutical Research Institute of Warsaw, Poland which provides the company the right to license the use of Genistein analogs for cancer treatment.
About Oncolin Therapeutics, Inc.
Headquartered in Houston, Texas, Oncolin Therapeutics, Inc. is a publicly traded biopharmaceutical company that engages in the discovery, development and commercialization of novel selective anticancer therapies. Additional information about Oncolin can be found on the web at www.oncolinthera.com.
Safe Harbor Statement
This press release contains statements that may constitute forward-looking statements, including the company’s ability to successfully acquire and develop technologies that are and may be acquired. These statements are based on current expectations and assumptions and involve a number of uncertainties and risks that could cause actual results to differ materially from those currently expected. For additional information about Oncolin’s future business and financial results, refer to Oncolin’s Quarterly Report on Form 10-QSB for the quarter ended December 31, 2007 and Annual Report on Form 10-KSB for the year ended March 31, 2007. Oncolin Therapeutics undertakes no obligation to update any forward-looking statement that may be made from time to time by or on behalf of the company, whether as a result of new information, future events or otherwise.
Contact:
Oncolin Therapeutics, Inc., Houston
J. Leonard Ivins, 832-426-7909
Investors@oncolinthera.com